"Lund-based cancer treatment company Lithea, developer of the LIT-platform - a technology enabling local treatment of solid tumours with an enhanced anti-cancer effect, recently announced that they have received a Certificate of Patent from the Japan Patent Office (JPO). This means that the JPO has approved the patent application and registered the patent making it valid until 2041. This is the Company's first patent to be granted in Japan for the LIT-platform technology."
"We are proud to announce that Lithea has secured patent approval in Japan. This milestone underscores our commitment to innovation and strengthens our position in delivering cutting-edge intratumoral therapies to patients worldwide. It also underscores our organization's ability to generate patentable inventions. says Ludvig Sjöberg, CEO of Lithea The patent provides the LIT-platform protection for treating cancer using the LIT-platform to deliver pharmaceutical drugs. Lithea has patents granted to date in Europe, Japan, and Singapore, with late-stage applications in the USA and China."
Lithea received a Certificate of Patent from the Japan Patent Office, registering LIT-platform patent protection until 2041. The patent covers use of the LIT-platform to deliver pharmaceutical drugs for local treatment of solid tumours with an enhanced anti-cancer effect. This constitutes Lithea's first granted patent in Japan and complements existing grants in Europe and Singapore. Late-stage patent applications remain in the USA and China. The milestone strengthens Lithea's position in delivering cutting-edge intratumoral therapies worldwide and reflects the organization's ability to generate patentable inventions.
Read at resund Startups
Unable to calculate read time
Collection
[
|
...
]